Teradyne (TER) Up 22.6% Since Last Earnings Report: Can It Continue?
Teradyne (TER) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
It has been about a month since the last earnings report for Teradyne (TER). Shares have added about 22.6% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Teradyne due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Teradyne Q3 Earnings & Revenues Beat Estimates
Teradyne reported third-quarter 2021 earnings of $1.59 per share, which surpassed the Zacks Consensus Estimate by 9.7% and increased 34.7% year over year.
Revenues of $951 million also surpassed the Zacks Consensus Estimate of $941.3 million. Further, the figure increased 16% year over year. Higher demand for both Test and Industrial Automation (“IA”) products drove top-line growth for the reported quarter.
Revenues from Semiconductor Test platforms, System Test business, IA, and Wireless Test business were $688 million, $103 million, $91 million, and $69 million, respectively.
Test revenues were driven by strength in Semiconductor Test and Wireless Test. Also, IA revenues increased because Universal Robots globally delivered high growth.
Test shipments remained high for the reported quarter. But, shipments from the IA business were low owing to supply constraints in the product lines.
Non-GAAP gross margin was 60.1%, expanding 407 basis points (bps) year over year.
GAAP operating expenses increased 31.4% year over year to $248.6 million. As a percentage of revenues, GAAP operating expenses increased 306 bps year over year to 26.2%.
Selling and administrative (S&A) expenses grew 16.4% year over year to $134.8 million. Engineering and development (E&D) increased 12.97% year over year to $107.2 million. S&A expenses expanded 5 bps while E&D expenses contracted 30 bps as a percentage of revenues.
Acquired intangible assets amortization (AIAA) expenses declined 13.9% year over year to $5.4 million. As a percentage of revenues, AIAA expenses contracted 20 bps year over year.
Consequently, non-GAAP operating margin was 33.9%, which expanded 101 bps from the year-ago quarter.
Balance Sheet & Cash Flow
As of Oct 3, 2021, Teradyne’s cash and cash equivalents (including marketable securities) were $1.31 billion, higher than $1.24 billion as of Jul 4, 2021.
Net cash provided by operating activities was $522.7 million for the third quarter versus $206.3 million in the prior quarter.
For the fourth quarter of 2021, Teradyne expects revenues between $820 million and $900 million.
Growing demand in Industrial/Automotive Test, Storage Test, and Industrial Automation is a major tailwind.
Non-GAAP earnings are expected between $1.14 and $1.40 per share for fourth-quarter 2021.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended upward during the past month. The consensus estimate has shifted 8.16% due to these changes.
Currently, Teradyne has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with a D. Charting a somewhat similar path, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Teradyne has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Teradyne, Inc. (TER): Free Stock Analysis Report
To read this article on Zacks.com click here.